NAD+ Benefits: What the Research Actually Shows

Short answer. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme that every cell uses to carry electrons through metabolism and to supply enzymes that repair DNA and regulate gene expression. It is not a peptide, and it is not a hormone. Human trials show consistently that oral NAD+ precursors raise NAD+ concentrations in blood, which is a real and measurable biochemical effect, but the evidence that raising those concentrations improves energy, metabolic health, strength, or the pace of aging is mixed and frequently null. The intravenous and injected NAD+ that wellness clinics advertise has, as of the most recent systematic review, no controlled outcome trials behind it at all.

What NAD+ is and what it does in the cell

NAD+ has two jobs, and confusing them is the source of most of the marketing around it.

The first job is redox chemistry. NAD+ and its reduced partner NADH form a shuttle that moves electrons through glycolysis, the citric acid cycle, and oxidative phosphorylation. In this role NAD+ is a catalyst in the strict sense. It is not consumed. It cycles between its oxidized and reduced states over and over, and what matters biologically is the ratio between the two rather than the absolute amount of either (Pandolfi et al., Molecular Biology Reports 2026, 10.1007/s11033-026-12351-3).

The second job drives the longevity interest. Several enzyme families use NAD+ as a substrate rather than a catalyst, breaking the molecule apart and consuming it. Poly(ADP-ribose) polymerase (PARP) enzymes do this during DNA repair, the sirtuin deacetylases during gene regulation, and CD38 in immune and metabolic signaling. NAD+ is the sole substrate for PARP and for the sirtuins (Massudi et al., PLoS ONE 2012, 10.1371/journal.pone.0042357).

That second role is why NAD+ can run down. A cofactor that only cycles does not deplete. A substrate destroyed every time an enzyme fires has to be continuously resynthesized, and if demand outruns supply, the pool shrinks.

Is NAD+ a peptide

No. This question gets asked often enough that it deserves a direct chemical answer rather than a hedge.

A peptide is a chain of amino acids joined by peptide bonds, which are amide linkages between the carboxyl group of one amino acid and the amino group of the next. BPC-157, Epitalon, and Thymosin Alpha-1 are peptides. They have amino acid sequences you can write out letter by letter.

NAD+ has no amino acids and no peptide bonds. It is a dinucleotide, which means two nucleotides joined together. One half is an adenine nucleotide, the same adenine found in DNA and ATP, attached to a ribose sugar. The other half is a nicotinamide nucleotide, built from the vitamin B3 derivative nicotinamide, also attached to a ribose. The two halves are bridged by a pyrophosphate linkage, not by an amide bond between amino acids. Its molecular formula is C21H27N7O14P2, its molecular weight is roughly 663.4 g/mol, and its CAS registry number is 53-84-9 (PubChem CID 5892).

So why does NAD+ appear in peptide catalogs and in searches for "NAD+ peptide"? Three reasons, none of them chemical. It is supplied by the same research-chemical vendors that supply research peptides. It arrives in the same format, a lyophilized powder in a light-protected vial with a batch certificate. And it is marketed to the same longevity and performance audience. Shared packaging is not shared chemistry. If a source calls NAD+ a peptide, that is a reliable signal it is not checking its chemistry, which is worth remembering when you read its other claims.

Why NAD+ levels decline with age

The best human evidence for the decline itself comes from tissue rather than blood. Massudi and colleagues analyzed pelvic skin samples from 49 people, newborns aged 0 to 1 plus patients aged 15 to 77, and found NAD+ concentrations correlated negatively with age in both men (r = -0.706, p = 0.001) and women (r = -0.537, p = 0.01). In the same samples, DNA damage rose with age in both sexes. PARP activity rose with age in men (r = 0.768, p less than 0.0001) and correlated inversely with tissue NAD+, while the authors reported these associations were less evident in women (Massudi et al., PLoS ONE 2012, 10.1371/journal.pone.0042357).

Note the design. This is a cross-sectional human tissue study, so it establishes that older skin contains less NAD+, and that in men it also contains more PARP activity, with the two tracking together. It does not establish that one causes the other, and it does not say anything about whether reversing the decline changes anything.

That gives one mechanism with direct human support. Accumulated oxidative DNA damage drives PARP hyperactivation, and because PARP consumes NAD+, sustained repair activity draws the pool down. Two further mechanisms are commonly proposed but rest on preclinical work rather than human data. CD38 is reported to rise with age and act as a second major consumer, evidence built from mouse tissue and cultured endothelial cells and macrophages, where factors secreted by senescent cells induced CD38 expression and NADase activity (Chini et al., Biochemical and Biophysical Research Communications 2019, 10.1016/j.bbrc.2019.03.199). The salvage pathway that recycles nicotinamide back into NAD+ is also thought to lose efficiency. These are mechanistic accounts of a measured decline, not a case that any intervention fixes it.

NAD+ vs NMN vs NR

This is where the human evidence is actually strongest, because the question is a biochemical one that a short trial can answer.

The cleanest comparison to date is a randomized, open-label, placebo-controlled, four-arm trial conducted at Nestlé Research in Lausanne, with 65 participants in the modified intention-to-treat analysis. Over 14 days of once-daily supplementation, nicotinamide riboside (NR) raised whole-blood NAD+ concentrations by 49.4 µM (95% CI 39.5 to 59.3) and nicotinamide mononucleotide (NMN) raised them by 43.1 µM (95% CI 32.7 to 53.4), both roughly a doubling relative to placebo. Plain nicotinamide did not produce a sustained increase (p = 0.461). The trial used 1,000 mg/day of NR, 1,000 mg/day of NMN, and 500 mg/day of nicotinamide (Christen et al., Nature Metabolism 2026, 10.1038/s42255-025-01421-8).

Two caveats belong with that result. The trial was run by a company with commercial interests in the category, and it was open-label rather than blinded. It is still the most direct head-to-head data available, and worth reading with those facts in view.

The same paper produced a mechanistic result that reframes how these compounds are usually described. When the researchers added NR and NMN directly to human whole blood outside the body, neither raised NAD+; both were degraded to their building blocks within 30 to 60 minutes. Nicotinic acid, by contrast, raised the NAD+ signal by roughly 170%. Using ex vivo fermentation with human gut microbiota, they showed that NR and NMN are converted by gut bacteria into nicotinic acid, which feeds NAD+ synthesis through the Preiss-Handler pathway. So NR and NMN may not be absorbed intact and delivered to cells as advertised, and may work substantially by being taken apart in the gut first. The authors are careful about how far this goes. They did not detect raised nicotinic acid in participants' venous blood, which they attribute to its slow release and rapid uptake, and they present the gut route as a proposed model rather than a demonstrated one.

A phase I pharmacokinetic trial adds the time course. Six healthy participants and six people with Parkinson's disease received 1,200 mg/day of either NR or NMN. Blood NAD+ rose slowly and plateaued after roughly two weeks, then declined with similarly slow kinetics once the supplement stopped. Cerebral NAD+, measured by phosphorus magnetic resonance spectroscopy, rose measurably after four weeks. Individual responses varied considerably but were not influenced by disease status or sex (Berven et al., iScience 2026, 10.1016/j.isci.2026.114764). This was a pharmacokinetic study, not a comparison trial, so it should not be read as ranking NR against NMN.

Where does that leave plain oral NAD+? Poorly positioned and largely untested. NAD+ is a larger, more charged molecule than either precursor, and no published human randomized trial shows that oral NAD+ raises blood NAD+ the way they do. Given that NR and NMN may themselves be broken down rather than absorbed intact, the case for the intact dinucleotide surviving oral delivery is weaker still.

NADH vs NAD+. These are not competing products. They are the same molecule in two oxidation states, oxidized (NAD+) and reduced (NADH), and cells interconvert them continuously. Notably, in the 14-day trial above, NADH and NADP levels were not significantly changed by any of the three precursors, even as NAD+ itself doubled.

What human trials actually show, benefit by benefit

The honest summary from a 2026 PRISMA-guided systematic review is that oral NR and NMN reliably do one thing and unreliably do everything else. Reviewing 113 eligible studies (33 human intervention studies and 80 rodent studies) published between January 2010 and October 2025, Gallagher and Emmanuel found that oral NR and NMN consistently demonstrated biochemical target engagement and were generally well tolerated over weeks to months, while effects on functional, metabolic, vascular, and other healthspan-relevant outcomes were heterogeneous and often null or endpoint-specific (Gallagher and Emmanuel, Ageing Research Reviews 2026, 10.1016/j.arr.2026.103057).

Energy and fatigue. NAD+'s role in energy metabolism is established biochemistry. The inference that supplementing it produces more perceived energy is a separate claim, and it is the single most common overreach in NAD+ marketing. Two randomized trials have measured something close to it, and they point in different directions.

In the first, 80 healthy middle-aged adults took placebo or 300, 600, or 900 mg of NMN daily for 60 days in a multicenter, double-blind, dose-ranging design. Scores on the SF-36 self-reported health survey improved significantly against placebo in all three treated groups at day 60 (Yi et al., GeroScience 2022, 10.1007/s11357-022-00705-1). Weigh that against its provenance. The trial was industry-sponsored, with three of its ten authors affiliated with an NMN supplier and two NMN manufacturers, the analysis was per-protocol rather than intention-to-treat, and one secondary endpoint was a consumer "biological age" calculator.

The second measured fatigue directly. In a double-blind, placebo-controlled trial, 108 older Japanese adults took 250 mg of NMN or placebo once daily for 12 weeks, split by morning or afternoon dosing, with fatigue assessed by the Jikaku-sho shirabe questionnaire. Drowsiness improved significantly in the afternoon NMN group, but also in the afternoon placebo group (Kim et al., Nutrients 2022, 10.3390/nu14040755).

So the position is one modest positive on a general-health questionnaire from a sponsor-run trial, one fatigue trial whose signal the placebo matched, and a body of largely null functional findings behind them. That is a long way from the claim that NAD+ supplementation gives people more energy.

Metabolic health. The most-cited positive result is a 10-week randomized, placebo-controlled, double-blind trial in which 25 postmenopausal women with prediabetes who were overweight or obese received NMN or placebo. Insulin-stimulated glucose disposal, measured by hyperinsulinemic-euglycemic clamp, and skeletal muscle insulin signaling both increased with NMN and did not change with placebo (Yoshino et al., Science 2021, 10.1126/science.abe9985). It drew a substantive published critique. Charles Brenner pointed out that the 13 women who received NMN had baseline hepatic lipid content of 6.3% against 14.8% in the 12 placebo recipients (p = 0.003), and argued that because liver fat clearance is a target of NMN, the trial was not effectively randomized (Brenner, Science 2021, 10.1126/science.abj1696). Both belong in any honest account.

Against that single trial sit two meta-analyses. Pooling 15 randomized trials of oral NMN at 250 to 2,000 mg/day over durations from 14 days to 24 weeks, Yang and colleagues found no significant effects on body weight, BMI, fasting glucose, HbA1c, lipid profiles, or systolic blood pressure. Diastolic blood pressure decreased slightly, and HOMA-IR showed a non-significant downward trend (Yang et al., Nutrients 2026, 10.3390/nu18142251). A separate review of 19 randomized trials found NAD+ precursors reduced total cholesterol and triglycerides but did not significantly affect other metabolic syndrome parameters, and rated the overall quality of evidence as very low to low using GRADE (Oliveira-Cruz et al., Hormone and Metabolic Research 2024, 10.1055/a-2382-6829).

Cardiovascular. A 2 x 6-week randomized, double-blind, placebo-controlled crossover trial of 1,000 mg/day NR in healthy middle-aged and older adults found the supplement well tolerated and effective at raising NAD+. On the cardiovascular side, the authors' own framing was that the results suggested future trials should further assess NR for blood pressure and arterial stiffness, which is a call for more research rather than a finding (Martens et al., Nature Communications 2018, 10.1038/s41467-018-03421-7).

A meta-analysis of 29 articles covering 8,664 participants did find significant pooled reductions in systolic blood pressure (-2.54 mmHg), diastolic blood pressure (-2.15 mmHg), C-reactive protein (-0.93 mg/L), and carotid intima-media thickness (-0.01 mm) with NAD+ precursor supplementation. The detail that matters is in the subgroup analysis. Effects were greatest at doses of 2 g or more, over durations beyond 12 weeks, and with nicotinic acid rather than nicotinamide (Lei et al., European Journal of Clinical Investigation 2023, 10.1111/eci.14078). High-dose nicotinic acid is niacin, a lipid-modifying agent with decades of use and its own side effect profile. Attributing that pooled cardiovascular signal to NR or NMN is a category error, and NAD+ marketing makes it routinely.

Cognition. The NADPARK trial gave 1,000 mg/day of NR or placebo to 30 newly diagnosed, treatment-naive Parkinson's patients for 30 days. NR was well tolerated and produced a significant but variable increase in cerebral NAD+. Participants whose brain NAD+ rose showed altered cerebral metabolism on FDG-PET, associated with mild clinical improvement (Brakedal et al., Cell Metabolism 2022, 10.1016/j.cmet.2022.02.001). This was a phase I safety and target-engagement trial in a disease population, not an efficacy trial and not a study of healthy cognition. It establishes that oral NR can reach the brain, not that doing so helps anyone think better. Working in the other direction, a meta-analysis noted that in people with mild cognitive impairment, NR was associated with lower short physical performance battery scores and slower chair-stand times.

Exercise performance and physical function. The pooled data are negative. A systematic review and meta-analysis of randomized trials in adults with a mean age from 60.9 to 83 found NMN had no significant effect on skeletal muscle index, handgrip strength, gait speed, or the five-time chair stand test, and a narrative synthesis found no improvement in knee extension strength, short physical performance battery, or thigh muscle mass. NR was associated with longer six-minute walking distance specifically in people with peripheral artery disease. The authors concluded that current evidence does not support NMN and NR supplementation for preserving muscle mass and function in this age group (Prokopidis et al., Journal of Cachexia, Sarcopenia and Muscle 2025, 10.1002/jcsm.13799).

A mechanistic trial points the same way. Twelve aged men received 1 g/day of NR for 21 days in a placebo-controlled, randomized, double-blind crossover design. NR did elevate the skeletal muscle NAD+ metabolome, confirming the compound reaches muscle. It did not alter mitochondrial bioenergetics. It did depress levels of circulating inflammatory cytokines, which is a genuine finding worth reporting alongside the null one (Elhassan et al., Cell Reports 2019, 10.1016/j.celrep.2019.07.043).

The counterweight is the Yi trial described above, where six-minute walking distance increased significantly against placebo in all three NMN groups at both day 30 and day 60 (all p less than 0.01), with the longest distances in the 600 mg and 900 mg groups. That population was healthy and middle-aged rather than older and sarcopenic, so it is not a direct contradiction of the meta-analysis, and the same industry-sponsorship and per-protocol caveats apply. The fair reading is that pooled evidence in older adults is null while a single sponsor-run trial in a younger group is positive.

Skin. Skin NAD+ falls with age, and that is well measured. What does not exist is a controlled human trial showing that raising NAD+ changes any skin outcome. The absence is worth stating plainly rather than filling with cell-culture results presented as if they were human evidence.

Aging reversal. The systematic review that assessed exactly this question concluded that NAD+ augmentation shows clear biological activity but that clinical effectiveness for anti-aging or wellness outcomes remains inconclusive. That is the current state of the evidence, and no amount of mechanism talk changes it.

The injected and IV NAD+ evidence gap

This is the section most NAD+ content skips, and it is the most important one.

The 2026 PRISMA-guided systematic review searched human and rodent intervention studies of NAD-related compounds given orally or parenterally from January 2010 to October 2025. Across 113 eligible studies, the finding on injected and intravenous NAD+ was not that the evidence was weak. It was that no eligible outcomes trials evaluated intravenous or intramuscular NAD+ itself for anti-aging or wellness indications. One nonrandomized intravenous NMN study met inclusion criteria, contributing mainly short-term safety and biomarker information. An intravenous NAD+ pharmacokinetic pilot was identified but lacked eligible clinical outcomes, so it counted only as contextual evidence (Gallagher and Emmanuel, Ageing Research Reviews 2026, 10.1016/j.arr.2026.103057).

Read that against a typical IV drip clinic's website and the gap is stark. The thing being sold has not been tested for the thing it is sold for.

What does exist is a tolerability comparison. Reyna and colleagues reviewed electronic medical records from clients at a commercial wellness provider who received four consecutive days of 500 mg intravenous NAD+ or intravenous NR, with 30 days of follow-up. Those given intravenous NAD+ reported moderate to severe gastrointestinal symptoms, increased heart rate, and chest pressure during infusions; those given intravenous NR experienced minor tongue, jaw, and arm tingling and mild cramping. All symptoms resolved when the infusion finished. Because the NAD+ symptoms required slowing the drip, infusions averaged 97 minutes for NAD+ against 37 minutes for NR. No significant changes appeared in ALT, AST, hsCRP, BUN/creatinine, or TSH (Reyna et al., Frontiers in Aging 2026, 10.3389/fragi.2026.1652582).

The design limits matter. This was retrospective, not randomized, not blinded, and the authors were affiliated with the provider whose infusions they evaluated. It is a useful real-world safety signal, not efficacy evidence.

Why does clinic marketing outrun the data? Because intravenous delivery feels like it should solve the absorption problem oral NAD+ obviously has, and because a same-day infusion with immediate physical sensations is easier to sell than a precursor that takes two weeks to plateau. The sensation is not the effect. A separate 2026 review noted that intravenous NAD+ is less well characterized than oral precursors and lacks robust clinical validation, and that NAD+ responses are nonlinear and shaped by route, age, and metabolic state rather than following a simple dose-response relationship (Pandolfi et al., Molecular Biology Reports 2026, 10.1007/s11033-026-12351-3).

Delivery forms compared

The last three rows are the honest answer to some of the most-searched NAD+ questions. Marketing for nasal, liposomal, and sublingual NAD+ typically borrows the oral precursor trial data and the intravenous clinic imagery, while the specific delivery form has no controlled human evidence of its own. Absence of evidence is not proof that a form does not work. It does mean that claims about it are not built on human trials.

Side effects and safety

For oral precursors over short durations, the tolerability record is reassuring. In the review of 15 NMN trials described above, 10 contributed to the safety analyses, across NMN doses of 250 to 2,000 mg/day and durations of 14 days to 24 weeks. Those pooled analyses found no increase in overall adverse events, serious adverse events, withdrawals due to adverse events, or system-specific adverse events, and no significant elevation of ALT or AST (Yang et al., Nutrients 2026, 10.3390/nu18142251). In the 14-day four-arm trial, only three adverse events across 65 participants were judged probably related to the product, one case each of abdominal pain, hypotension, and headache (Christen et al., Nature Metabolism 2026, 10.1038/s42255-025-01421-8).

At higher exposures, a phase I safety trial randomized 20 people with Parkinson's disease to NR 1,500 mg twice daily or placebo for four weeks. All 20 completed. There were no moderate or severe adverse events and no significant difference in mild adverse events. NR recipients showed a slight initial rise in serum homocysteine, while the integrity of the methyl donor pool remained intact (Berven et al., Nature Communications 2023, 10.1038/s41467-023-43514-6).

Two distinctions are worth holding. Flushing and gastrointestinal symptoms at high doses are characteristic of nicotinic acid rather than NR or NMN, and they are the reason its use as an NAD+ booster is limited (Christen et al., Nature Metabolism 2026, 10.1038/s42255-025-01421-8). And the intravenous symptom profile described above, moderate to severe gastrointestinal symptoms, increased heart rate, and chest pressure, was infusion-rate dependent and resolved on completion.

Long-term safety is genuinely unknown. The trials above run from 14 days to 24 weeks. Both the systematic review and the NMN safety meta-analysis explicitly call for larger studies with longer follow-up before conclusions about long-term safety can be drawn. Nobody has data on years.

On caution, the most factual thing to say is who the trials excluded. The 14-day trial excluded people with any chronic or acute medical condition or significant medical history, people using prescription drugs known to potentially interact with NAD+ precursors including tetracycline antibiotics, anticoagulants, and bile acid sequestrants, and people taking related supplements. Pregnant and breastfeeding women are not represented in this literature. The evidence base describes healthy adults and a few specific patient groups, and it does not extend to anyone outside those populations.

Regulatory status

NAD+ is not approved by the FDA for any therapeutic use. There is no FDA-approved NAD+ drug for aging, energy, cognition, addiction, or any other indication, and intravenous NAD+ administered at wellness clinics is not an approved therapy.

The NMN story is worth one paragraph because it is widely reported out of date. In late 2022 the FDA concluded that NMN was excluded from the dietary supplement definition under the drug preclusion clause of the Federal Food, Drug, and Cosmetic Act, on the grounds that it had been authorized for investigation as a new drug. Industry groups filed a citizen petition in March 2023 and litigation followed in 2024. In two letters dated September 29, 2025, the FDA reversed that position, concluding that although NMN had been authorized for drug investigation, it had been marketed as a dietary supplement in the United States before that authorization, and therefore was not excluded. Follow-up letters dated December 2, 2025 to companies that had submitted new dietary ingredient notifications reiterated that NMN may be lawfully marketed. The agency did not issue interpretive guidance defining what counts as substantial clinical investigation, so the broader ambiguity in the drug preclusion clause remains. Nicotinamide riboside has been marketed as a dietary supplement throughout.

None of that applies to NAD+ sold as a research chemical. Research-use-only material is not a dietary supplement, not a drug, and not intended for human consumption in any form. It occupies a separate category with separate rules. This paragraph is a description of the regulatory landscape and not legal advice.

What a COA proves and what it does not

If you are sourcing NAD+ as a research compound, the Certificate of Analysis is the document that matters, and understanding its limits is the difference between reading it and being reassured by it.

A batch-matched COA reports two analyses. High-performance liquid chromatography (HPLC) separates the sample and quantifies purity, answering how much of the material is the target compound. Mass spectrometry confirms identity by measuring the mass-to-charge profile, answering whether the compound is what the label says. Together they describe one specific tested lot under one stated method.

Here is what a COA does not establish, and this is the part marketing tends to blur. It does not establish sterility, endotoxin status, clinical safety in humans by any route, or biological efficacy. A 99%+ purity figure tells you the vial contains what the label says. It tells you nothing about whether that compound does anything useful in a living person, and every piece of evidence reviewed above sits outside what purity testing can address. Purity is a manufacturing claim. Safety and efficacy are clinical claims, and a high number in the first column is not evidence for the second.

PrimeTime BioLabs supplies NAD+ 500 mg as a research compound, described on the product page as a sterile lyophilized powder, verified by HPLC and mass spectrometry, and shipped with a batch-matched COA listing the lot number, measured purity, and analysis date for the specific vial received. Note that the sterility description is a product-handling statement from the supplier and not something the HPLC and mass spectrometry results on the COA can demonstrate. It is supplied strictly for in-vitro laboratory research. It is not a supplement, not for human or animal use, and has not been evaluated by the FDA for any purpose.

Researchers working on adjacent questions also look at MOTS-c, a mitochondrial-derived peptide studied in research models of AMPK activation and cellular energy homeostasis, and at Epitalon and Thymosin in longevity research contexts. All are supplied on the same research-use-only basis, and all carry the same caveat as NAD+. A certificate describes the material, not its effect.

For research use only. Not for human or veterinary use.